Steven Cohen Also Initiates Stake in Retrophin Inc (RTRX)

Steven Cohen, in a new filing with the SEC disclosed initiating a stake in Retrophin Inc (NASDAQ:RTRX). According to the filing, Mr. Cohen holds a total of 1.29 million shares of the company. The stake is passive by nature and amasses 5.6% of the company’s common stock.


The position is held in aggregate by SAC Capital Advisors and Sigma Capital Management, each owning around 976,500 shares and 315,000 shares respectively.

Mr. Cohen went bullish on Retrophin Inc (NASDAQ:RTRX) a couple of weeks after the company started trading on NASDAQ Global Market. The company conducted an underwritten public offering in which it sold $40.0 million worth of its common stock. Following the offering, the company’s stock was approved to move its stock to NASDAQ from OTCQB where it traded previously.

Earlier today, another hedge fund, Broadfin Capital, led by Kevin Kotler also disclosed a passive stake in the company, which amasses 1.61 million shares, equal to 6.93% of the common stock.

The stock of Retrophin Inc (NASDAQ:RTRX) gained over 80%, while during 2013, the stock advanced by a whooping 6,000%. Last month the company announced that it has a new clinical development candidate, RE-034 (cosyntropin) that is expected to be able to treat infantile spasm, as well as West Syndrome, a form of epilepsy. The company will file an Investigational New Drug Application and will initiate Phase 1 trial in the first half of this year. Following that, the company will launch Phase 3 trials.

Also in December, Retrophin Inc (NASDAQ:RTRX) closed its stake in Transcept Pharmaceuticals Inc (NASDAQ:TSPT). The company also has withdrawn its offer to acquire Transcept launched earlier in September. According to Retrophin, the deal was canceled since the board of Transcept refused to engage in substantive discussions and because its cash has declined, which makes the offering price not compelling for the shareholders of Retrophin.

Disclosure: none

Recommended Reading:

Mario Gabelli Is Bullish on The Pep Boys – Manny, Moe & Jack (PBY) and Diebold Incorporated (DBD)

Millenium Management Continues Selling Liberator Medical Holdings Inc (LBMH) Stock

Ken Griffin Boosts Stake in Affymetrix, Inc. (AFFX); Cuts Penn Virginia Corporation (PVA)


Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!